Synaptic density and tau pathology in Alzheimer’s disease (SYNAPSE)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517636-22-00

Enrollment

Registered

2024-12-10

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Brief summary

Quantification of brain regional [18F]SynVesT-1 uptake (synaptic density) and regional [ 18F]flortaucipir uptake (tau)

Detailed description

association between [18F]Flortaucipir (tau) binding and [18F]SynVesT-1 (synaptic density) binding

Interventions

DRUG18F-Synvest-1

DRUGFlortaucipir

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Quantification of brain regional [18F]SynVesT-1 uptake (synaptic density) and regional [ 18F]flortaucipir uptake (tau)	—

Secondary

Measure	Time frame
association between [18F]Flortaucipir (tau) binding and [18F]SynVesT-1 (synaptic density) binding	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026